Bioventus Inc.
6.94+0.23 (+3.43%)
Oct 28, 4:00:01 PM EDT · NasdaqGS · BVS · USD
Key Stats
Market Cap
464.23MP/E (TTM)
231.33Basic EPS (TTM)
0.03Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Bioventus posted Q2 net sales of $147.7M, down 2.4% y/y but up 3.1% q/q (derived), as Surgical Solutions grew 9.5% y/y on BGS and ultrasonics volume while Restorative Therapies dropped 32.2% y/y from the Advanced Rehabilitation divestiture. Gross margin edged up to 69.1%, a 0.5-point y/y gain, thanks to favorable pricing abroad, yet operating income swung to $18.4M from a $31.5M loss, fueled by $17.6M lower SG&A—mainly slashed litigation costs and commissions. Diluted EPS hit $0.11, matching basic on 68.5M shares with no anti-dilution flags. Cash dipped to $32.9M after $6.6M operating outflow, but free cash flow turned negative at -$5.1M (derived) amid capex; total debt stood at $341.2M with $35M revolver availability, soon refinanced via July's $300M term loan extending to 2030. Momentum builds in pain treatments. Shareholder suits linger.
8-K
Bioventus Q2 organic revenue up 6.2%
Bioventus reported Q2 revenue of $147.7 million, down 2.4% from last year due to the Advanced Rehabilitation divestiture, yet organic revenue climbed 6.2% on double-digit gains in Surgical Solutions and Restorative Therapies. Non-GAAP EPS rose 31% to $0.21, with cash from operations surging 71% to $25.9 million; the company secured FDA clearance for TalisMann and StimTrial nerve pain devices and a new $300 million term loan slashing interest by over $2 million annually. Guidance holds steady for 2025 revenue of $560-570 million and Non-GAAP EPS of $0.64-0.68. Organic growth accelerates.
8-K
Bioventus Inc. announces a new $400M credit facility with a $100M revolver and $300M term loan A, maturing in 5 years, to refinance existing debt and fund general corporate purposes. The facility features a leverage ratio starting at 4.00x, stepping down to 3.50x, and an interest coverage ratio of 2.50x.
Bioventus Inc. has entered into a new $400 million credit facility, consisting of a $100 million revolving credit facility and a $300 million term loan A facility, both maturing in five years. The facility replaces the existing credit agreement and is secured by substantially all assets of Bioventus LLC and its subsidiaries. The agreement includes financial covenants with a maximum consolidated total net leverage ratio of 4.00 to 1.00 initially, stepping down to 3.50 to 1.00 thereafter, and a minimum consolidated interest coverage ratio of 2.50 to 1.00. The credit facility is intended to refinance existing debt and support general corporate purposes.
8-K
FDA clears Bioventus PNS products
Bioventus snagged FDA 510(k) clearances for TalisMann and StimTrial on July 30, 2025, bolstering its peripheral nerve stimulation lineup for chronic pain. TalisMann targets deeper nerves with integrated tech for long-term relief, while StimTrial enables trial assessments to boost adoption. Limited U.S. launch hits Q3 2025; full rollout follows in early 2026. This taps a PNS market growing over 20% yearly toward $500 million by 2029, yet commercialization risks loom.
8-K
Bioventus elects directors, ratifies auditors
Bioventus Inc. held its 2025 Annual Meeting on June 3, 2025, with 89.76% of shares present. Stockholders elected six Class I directors—Robert E. Claypoole, Philip G. Cowdy, Michelle McMurry-Heath, Guido J. Neels, Guy P. Nohra, and Martin P. Sutter—to serve until 2026, despite notable withholding for Sutter. They ratified Grant Thornton LLP as auditors for the fiscal year ending December 31, 2025. Continuity holds firm.
AORT
Artivion, Inc.
45.26+0.52
BSX
Boston Scientific Corporation
100.97-1.46
ENOV
Enovis Corporation
32.86+0.00
GMED
Globus Medical, Inc.
62.75-0.51
NAOV
NanoVibronix, Inc.
5.89+0.13
NVNO
enVVeno Medical Corporation
0.71-0.02
SIBN
SI-BONE, Inc.
15.79+0.13
SNWV
SANUWAVE Health, Inc.
31.04+0.02
VERO
Venus Concept Inc.
2.14-0.05
ZIMV
ZimVie Inc.
18.99+0.00